Open AccessWeekly vs Every-3-Week Carboplatin with Weekly Paclitaxel in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Retrospective Analysis
Author(s) -
Kara K Landry,
Jessica L Lyon,
Kitty Victoria,
P Nick Changizzadeh,
Bernard F. Cole,
Bhargavi Pulluri,
William M. Sikov,
Marie Wood
Publication year - 2022
Publication title -
breast cancer
Language(s) - English
Resource type - Journals
ISSN - 1179-1314
DOI - 10.2147/bctt.s342635
Subject(s) - medicine , carboplatin , surgical oncology , paclitaxel , breast cancer , oncology , chemotherapy , triple negative breast cancer , neoadjuvant therapy , retrospective cohort study , triple negative , cancer , cisplatin
Adding carboplatin to weekly paclitaxel as part of neoadjuvant chemotherapy (NACT) for stage II-III triple negative breast cancer (TNBC) has been shown to significantly increase the pathologic complete response (pCR) rate. Hematologic toxicities associated with every 3-week dosing of carboplatin have led some oncologists to explore weekly dosing as an alternative, but there are little published data comparing the two dosing schedules.